Marvel Biosciences Corp. has expanded its private placement offering to include investors in Quebec, with updated documents available in English and French. The company focuses on developing new synthetic derivatives of approved drugs to target additional diseases, aiming to reduce development risks and costs. Marvel is advancing treatments for neurological and non-neurological conditions and exploring new targets to grow its pipeline. This expansion could attract more investment to support its drug redevelopment strategy.
Marvell Technology is recognized as a key player in data center connectivity and custom silicon, recently endorsed by Nvidia's CEO Jensen Huang, who suggested it could become a trillion-dollar company. The company’s innovative memory architecture, in...
Marvell Technology, a key player in AI infrastructure, has raised its fiscal year 2027 revenue forecast to $11.5 billion. The company expects its data center and interconnect segments to grow 50% and 70% year-over-year, respectively, driven by partne...
Marvell Technology has won a broad custom silicon partnership with Alphabet/Google, covering AI accelerators and networking controllers. This deal strengthens Marvell's position in high-growth markets like optical networking and custom silicon, leadi...
Marvell Technology's stock rose 6% following a deal allowing Google to buy up to $12.2 billion in shares at $206.58 each, tied to targets through fiscal 2033. This deal is part of a broader partnership on custom chips, including products linked to Go...
Marvell Technology has issued Google warrants for nearly 59 million shares, potentially giving Google a 7% stake if it purchases $12.2 billion worth of custom AI silicon by 2033. This deal aligns incentives by tying Google's equity gain to Marvell's ...
